PGX INFO FROM HOMEWORK EXAM QUESTIONS WITH CORRECT ANSWERS
PD1 vs PD-L1 - CORRECT ANSWER✅✅PD1 is the receptor (expressed in T cells), PD-L1 is the ligand
(expressed in cancer cells)
PD-1 blockers - CORRECT ANSWER✅✅Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab
(Libtayo)
PD-L1 blockers - CORRECT ANSWER✅✅Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab
(Imfinzi)
Therapies targeting BRCA1 - CORRECT ANSWER✅✅Olaparib, Niraparib, Talazoparib, Rucaparib
Therapies targeting KRAS - CORRECT ANSWER✅✅Binimetinib, Trametinib, Cobimetinib
KRAS-G12C Inhibitor - CORRECT ANSWER✅✅AMG 510
CDK4/CDK6 Inhibitors - CORRECT ANSWER✅✅Palbociclib, Ribociclib, Abemaciclib
Pembrolizumab (Keytruda) - CORRECT ANSWER✅✅PD-1 blocker
Nivolumab (Opdivo) - CORRECT ANSWER✅✅PD-1 blocker
Cemiplimab (Libtayo) - CORRECT ANSWER✅✅PD-1 blocker
Atezolizumab (Tecentriq) - CORRECT ANSWER✅✅PD-L1 blocker
Avelumab (Bavencio) - CORRECT ANSWER✅✅PD-L1 blocker
Durvalumab (Imfinzi) - CORRECT ANSWER✅✅PD-L1 blocker
PD1 vs PD-L1 - CORRECT ANSWER✅✅PD1 is the receptor (expressed in T cells), PD-L1 is the ligand
(expressed in cancer cells)
PD-1 blockers - CORRECT ANSWER✅✅Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab
(Libtayo)
PD-L1 blockers - CORRECT ANSWER✅✅Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab
(Imfinzi)
Therapies targeting BRCA1 - CORRECT ANSWER✅✅Olaparib, Niraparib, Talazoparib, Rucaparib
Therapies targeting KRAS - CORRECT ANSWER✅✅Binimetinib, Trametinib, Cobimetinib
KRAS-G12C Inhibitor - CORRECT ANSWER✅✅AMG 510
CDK4/CDK6 Inhibitors - CORRECT ANSWER✅✅Palbociclib, Ribociclib, Abemaciclib
Pembrolizumab (Keytruda) - CORRECT ANSWER✅✅PD-1 blocker
Nivolumab (Opdivo) - CORRECT ANSWER✅✅PD-1 blocker
Cemiplimab (Libtayo) - CORRECT ANSWER✅✅PD-1 blocker
Atezolizumab (Tecentriq) - CORRECT ANSWER✅✅PD-L1 blocker
Avelumab (Bavencio) - CORRECT ANSWER✅✅PD-L1 blocker
Durvalumab (Imfinzi) - CORRECT ANSWER✅✅PD-L1 blocker
